Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.0
Journals
NeuroSci
Special Issues
New Therapeutic Approaches in Neurological Conditions
share announcement

New Therapeutic Approaches in Neurological Conditions

A special issue of NeuroSci (ISSN 2673-4087).

Deadline for manuscript submissions: 31 December 2026 | Viewed by 1042

Special Issue Editor

Prof. Dr. Araceli Ortiz-Rubio

E-Mail Website
Guest Editor
Department of Physical Therapy, Faculty of Health Sciences, University of Granada, 18016 Granada, Spain
Interests: activity; chronic diseases; neurology; neurodegenerative; occupation; participation; rehabilitation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Neurological disorders represent a leading cause of disability worldwide, with conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and stroke posing immense challenges to global health. Despite advances in diagnosis, therapeutic options often remain limited, focusing on symptom management rather than a cure or disease modification. This underscores the critical and urgent need for innovative research into novel therapeutic strategies, including gene and cell-based therapies, precision medicine, neuroprotective agents, neuromodulation, and drug repurposing, which hold promise for altering disease trajectories and improving patient outcomes.

We are pleased to invite you to participate in our Special Issue. This issue aims to collate cutting-edge research and comprehensive reviews on emerging and innovative treatments for neurological diseases. Aligned with the journal's scope of publishing high-impact research on the molecular, cellular, and systemic mechanisms of neurological disorders and their treatment, this collection seeks to provide a focused forum on translational and clinical therapeutic advances.

In this Special Issue, original research articles, reviews, and meta-analyses are welcome. Research areas may include (but are not limited to) the following:

  • novel pharmacological targets and drug delivery systems;
  • advances in nueromodulations;
  • gene therapy;
  • physical and occupational interventions;
  • cognitive and behavioral therapies;
  • dietary and lifestyle interventions;
  • digital and technology-based therapies;
  • AI treatment and combined and integrative approaches.

I look forward to hearing from you.

Prof. Dr. Araceli Ortiz-Rubio
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. NeuroSci is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacological
  • multiple sclerosis
  • neurological
  • nervous system diseases
  • neuronal plasticity
  • non-drug therapies
  • rehabilitation
  • stroke
  • therapeutics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

27 pages, 2834 KB  
Article
Rapamycin and Minocycline Treatment Does Not Rescue Behavioral and Molecular Changes Induced by Early-Life Seizures in Female Mice
by Sydney F. Pell, Katherine J. Blandin, Taylor R. Bradish, Chloe V. Lau, Danielle Santana-Coelho, Madison Wallis, Colton W. Kelley, Josh J. Thayil, Ashley Smelley, Gautham Cheliah, David A. Narvaiz, Kendall N. Lally, Leighton Douglas and Joaquin N. Lugo
NeuroSci 2026, 7(3), 55; https://doi.org/10.3390/neurosci7030055 - 5 May 2026
Viewed by 369
Abstract
Early-life seizures lead to long-term behavioral deficits, stimulate cytokine release, and disrupt the intracellular PI3K/AKT/mTOR signaling pathway. This study examined whether inhibiting the mTOR pathway, neuroinflammatory signaling, or both reduces behavioral comorbidities in adulthood. Female C57BL/6J mice received kainic acid on postnatal day [...] Read more.
Early-life seizures lead to long-term behavioral deficits, stimulate cytokine release, and disrupt the intracellular PI3K/AKT/mTOR signaling pathway. This study examined whether inhibiting the mTOR pathway, neuroinflammatory signaling, or both reduces behavioral comorbidities in adulthood. Female C57BL/6J mice received kainic acid on postnatal day 10 to induce status epilepticus. Three hours later, the mice were treated with saline, minocycline, rapamycin, or both. Three months later, behavioral assessments were conducted that measured activity, anxiety, social behavior, repetitive behavior, and learning. Early-life seizures resulted in social behavior deficits in the social chamber test, altered anxiety in the elevated plus maze, and an increase in repetitive behavior in the nose poke assay. Rapamycin and minocycline/rapamycin groups showed reduced distance traveled in the saline groups. We did not find any changes in cytokines IL6, IL-1β, and TNFα in the hippocampus or cortex using RT-qPCR. Through Western blotting, we found that rapamycin reduced the phosphorylated S6 levels. Minocycline decreased phosphorylated S6 in controls, but restored phosphorylated S6 levels in the seizure group. Early-life seizures had long-term impacts on behavioral comorbidities. Rapamycin and minocycline, alone or combined, did not restore the behavioral or molecular changes after early-life seizures. These findings clarify the behavioral outcomes after early-life seizures and therapeutic modulation. Full article
(This article belongs to the Special Issue New Therapeutic Approaches in Neurological Conditions)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

19 pages, 676 KB  
Review
Vagus Nerve Stimulation in Alzheimer’s Disease and Mild Cognitive Impairment: Current Evidence and Future Directions
by Ruth Narramore, Mudasar Aziz, Sheharyar Baig, Joyce S. Balami, Arshad Majid and Ali N. Ali
NeuroSci 2026, 7(3), 52; https://doi.org/10.3390/neurosci7030052 - 27 Apr 2026
Viewed by 344
Abstract
Vagus nerve stimulation (VNS) may improve cognition and promote underlying brain health through various mechanisms including the noradrenaline and cholinergic pathways. Whilst early human studies used invasive devices (iVNS), recent decades have seen the emergence of non-invasive devices that stimulate the vagus nerve [...] Read more.
Vagus nerve stimulation (VNS) may improve cognition and promote underlying brain health through various mechanisms including the noradrenaline and cholinergic pathways. Whilst early human studies used invasive devices (iVNS), recent decades have seen the emergence of non-invasive devices that stimulate the vagus nerve transcutaneously (tVNS) via either the cervical branches in the neck (tcVNS) or the auricular branch in the ear (taVNS). With this increase in more accessible devices, tVNS is gaining interest as a novel therapy in mild cognitive impairment (MCI) and Alzheimer’s disease (AD). This targeted review aims to understand the current evidence in human trials in this specific population. PubMed, Cochrane, EMBASE, MEDLINE, and Google Scholar were searched. Six human interventional studies were found (one iVNS; five taVNS). VNS is well tolerated and study designs demonstrate feasibility within this population for future blinded and appropriately powered long-term studies with participants applying tVNS at home. However, protocols and tVNS settings remain variable. Working memory domains such as verbal fluency and 3D processing show the most promise but global cognitive scores were also sensitive in some cases. The role of biomarkers of tVNS activity and its effect on AD markers and neuroinflammation should be considered in the design of future studies. Full article
(This article belongs to the Special Issue New Therapeutic Approaches in Neurological Conditions)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop